Abstract
In recent studies performed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD), we have demonstrated that activation of the metabotropic glutamate 2 (mGlu2) receptor with the orthosteric agonist (OA) LY-354,740 and the positive allosteric modulator (PAM) LY-487,379 is effective at alleviating both dyskinesia and psychosis-like behaviours (PLBs) triggered by the administration of l-3,4-dihydroxyphenylalanine (l-DOPA). Because mGlu2 OAs and PAMs bind to different sites on the receptor, we hypothesised that greater reductions of dyskinesia and PLBs would be obtained upon concurrent administration of LY-354,740 and LY-487,379. In experiments performed in six MPTP-lesioned marmosets, we administered LY-354,740 (0.1 mg/kg), LY-487,379 (1 mg/kg), LY-354,740 (0.1 mg/kg) + LY-487,379 (1 mg/kg), or vehicle, in combination with l-DOPA and determined the effect of each treatment on dyskinesia, PLBs, and parkinsonism. When compared to vehicle, LY-354,740 and LY-487,379, administered alone or concurrently, significantly reduced dyskinesia. The combination LY-354,740 + LY-487,379 provided mild additional benefit when compared to LY-487,379 alone, but not compared to LY-354,740. For PLBs, when compared to vehicle treatment, LY-354,740, LY-487,379, and combination thereof all alleviated the abnormal behaviours, but the combination LY-354,740 + LY-487,379 did not provide greater relief than either drug alone. The anti-parkinsonian effect of l-DOPA was not altered by any of the treatments. Our results provide further evidence that mGlu2 activation might be a novel approach to treat l-DOPA-induced dyskinesia and dopaminergic psychosis in PD. However, they do not suggest that greater therapeutic effect would be achieved upon combining an mGlu2 OA and an mGlu2 PAM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383(9916):533–540. https://doi.org/10.1016/S0140-6736(13)62106-6
Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M (2012) Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 62(7):2184–2191. https://doi.org/10.1016/j.neuropharm.2012.01.010
Foster DJ, Conn PJ (2017) Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron 94(3):431–446. https://doi.org/10.1016/j.neuron.2017.03.016
Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63(9):1343–134410.1001/archneur.63.9.1343
Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM (2010) Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 37(1):86–95
Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, Gonzalez-Maeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5):1011–1023. https://doi.org/10.1016/j.cell.2011.09.055
Frouni I, Hamadjida A, Kwan C, Bédard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC, Beaudry F, Huot P (2019) Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2019.107725
Gaudette F, Hamadjida A, Bedard D, Nuara SG, Beaudry F, Huot P (2017) Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1061–1062:392–398. https://doi.org/10.1016/j.jchromb.2017.07.007
Gaudette F, Hamadjida A, Bedard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P (2018) Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset. J Chromatogr B Analyt Technol Biomed Life Sci 1093–1094:1–7. https://doi.org/10.1016/j.jchromb.2018.06.036
Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183):93–97. https://doi.org/10.1038/nature06612
Gregory KJ, Conn PJ (2015) Molecular insights into metabotropic glutamate receptor allosteric modulation. Mol Pharmacol 88(1):188–202. https://doi.org/10.1124/mol.114.097220
Hamadjida A, Nuara SG, Veyres N, Frouni I, Kwan C, Sid-Otmane L, Harraka MJ, Gourdon JC, Huot P (2017) The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset. Psychopharmacology 234(6):905–911. https://doi.org/10.1007/s00213-017-4530-z
Hamadjida A, Nuara SG, Bedard D, Frouni I, Kwan C, Gourdon JC, Huot P (2018a) Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. Naunyn Schmiedebergs Arch Pharmacol 391(12):1339–1345. https://doi.org/10.1007/s00210-018-1549-6
Hamadjida A, Nuara SG, Bedard D, Gaudette F, Beaudry F, Gourdon JC, Huot P (2018b) The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset. Neuropharmacology 139:61–67. https://doi.org/10.1016/j.neuropharm.2018.06.038
Hamadjida A, Nuara SG, Gourdon JC, Huot P (2018c) The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset. Prog Neuropsychopharmacol Biol Psychiatry 81:367–371. https://doi.org/10.1016/j.pnpbp.2017.09.001
Hamadjida A, Nuara SG, Gourdon JC, Huot P (2018d) Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease. J Neural Transm (Vienna) 125(9):1355–1360. https://doi.org/10.1007/s00702-017-1830-8
Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 2 study): interim results of an open-label safety study. J Parkinsons Dis 7(3):511–522. https://doi.org/10.3233/JPD-171134
Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney multicenter study of parkinson's disease: non-l-DOPA-responsive problems dominate at 15 years. Mov Disord 20(2):190–199. https://doi.org/10.1002/mds.20324
Howell DC (2006) Statistical methods for psychology, 6th edn. Wadsworth Publishing, Belmont, p 768
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci 31(19):7190–7198. https://doi.org/10.1523/JNEUROSCI.1171-11.2011
Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2012a) The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. PLoS ONE 7(9):e45587. https://doi.org/10.1371/journal.pone.0045587
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2012b) l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology 63(5):829–836. https://doi.org/10.1016/j.neuropharm.2012.06.012
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM (2014) UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 82:76–87. https://doi.org/10.1016/j.neuropharm.2014.01.012
Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46(15):3189–3192. https://doi.org/10.1021/jm034015u
Kent JM, Daly E, Kezic I, Lane R, Lim P, De Smedt H, De Boer P, Van Nueten L, Drevets WC, Ceusters M (2016) Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry 67:66–73. https://doi.org/10.1016/j.pnpbp.2016.01.009
Kwan C, Frouni I, Bedard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P (2019) 5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review. Exp Brain Res 237(2):435–442. https://doi.org/10.1007/s00221-018-5434-9
McColm J, Brittain C, Suriyapperuma S, Swanson S, Tauscher-Wisniewski S, Foster J, Soon D, Jackson K (2017) Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects. Br J Clin Pharmacol 83(8):1654–1667. https://doi.org/10.1111/bcp.13252
Di Menna L, Joffe ME, Iacovelli L, Orlando R, Lindsley CW, Mairesse J, Gressèns P, Cannella M, Caraci F, Copani A (2018) Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system. Neuropharmacology 128:301–313
Pahwa R, Hauser RA (2017) ADS-5102 (Amantadine) extended release for levodopa-induced dyskinesia. JAMA Neurol 74(12):1507–1508. https://doi.org/10.1001/jamaneurol.2017.3205
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol 74(8):941–949. https://doi.org/10.1001/jamaneurol.2017.0943
Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y (2005) Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49(Suppl 1):57–69. https://doi.org/10.1016/j.neuropharm.2005.03.006
Postma JU, Van Tilburg W (1975) Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 23(5):212–215
Roberts C (2006) ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 7(7):653–660
Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, Bristow LJ, Varney MA, Daggett LP (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64(4):798–810. https://doi.org/10.1124/mol.64.4.798
Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL, Burnett JP, Belegaje R, Bleakman D, Monn JA (1997) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36(1):1–11
Sid-Otmane L, Hamadjida A, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F, Panisset M, Huot P (2020) Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Eur J Pharmacol 873:172957. https://doi.org/10.1016/j.ejphar.2020.172957
Siegel S, Castellan NJ Jr (1988) Nonparametric statistics for the behavioral sciences, 2nd edn. McGraw-Hill Humanities, New York
Stansley BJ, Conn PJ (2019) Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. Trends Pharmacol Sci 40(4):240–252. https://doi.org/10.1016/j.tips.2019.02.006
Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O (2016) A Phase 2A Trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 31(9):1373–1380. https://doi.org/10.1002/mds.26659
Veyres N, Hamadjida A, Huot P (2018) Predictive value of Parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey. J Pharmacol Exp Ther 365(2):379–397. https://doi.org/10.1124/jpet.117.247171
Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 21(11):1879–1891. https://doi.org/10.1002/mds.21073
Zhang J, Qu FR, Nakatsuka A, Nomura T, Nagai M, Nomoto M (2003) Pharmacokinetics of l-DOPA in plasma and extracellular fluid of striatum in common marmosets. Brain Res 993(1–2):54–58
Funding
PH has received research support from Parkinson Canada, Fonds de Recherche Québec–Santé, the Weston Brain Institute (Grant no. TR150146), the Michael J Fox Foundation for Parkinson’s Research, and the Natural Sciences and Engineering Research Council of Canada and Healthy Brains for Healthy Lives.
Author information
Authors and Affiliations
Contributions
AH, SN, JC, and PH conceived and designed research. AH, SN, CK, DB, IF, and JC conducted experiments. PH analysed data. PH wrote the manuscript. All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
Experiments were approved by McGill University and the Montreal Neurological Institute Animal Care Committees, which are in accordance with the regulations defined by the Canadian Council on Animal Care.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nuara, S.G., Hamadjida, A., Kwan, C. et al. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset. J Neural Transm 127, 1023–1029 (2020). https://doi.org/10.1007/s00702-020-02185-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-020-02185-z